Sun Pharmaceutical Industries Limited (BOM:524715)
India · Delayed Price · Currency is INR | Market Cap | 3.81T |
| Revenue (ttm) | 537.77B |
| Net Income (ttm) | 103.72B |
| Shares Out | n/a |
| EPS (ttm) | 43.25 |
| PE Ratio | 36.71 |
| Forward PE | 31.19 |
| Dividend | 16.00 (1.00%) |
| Ex-Dividend Date | Jul 7, 2025 |
| Volume | 24,750 |
| Average Volume | 92,849 |
| Open | 1,581.25 |
| Previous Close | 1,598.65 |
| Day's Range | 1,581.25 - 1,600.45 |
| 52-Week Range | 1,555.00 - 1,960.20 |
| Beta | n/a |
| RSI | 31.58 |
| Earnings Date | Jul 31, 2025 |
About BOM:524715
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respira... [Read more]
Financial Performance
In 2024, BOM:524715's revenue was 525.78 billion, an increase of 8.42% compared to the previous year's 484.97 billion. Earnings were 109.29 billion, an increase of 14.12%.
Financial StatementsNews
Nifty 50 top losers today, August 6: Wipro, Sun Pharma, Jio Financial Services, Tech Mahindra and more
Indian stock markets continued their downward momentum for a second straight day on August 6, with benchmark indices closing in the red amid weak investor sentiment. The Nifty 50 slipped below the psy...
Raymond to Dr Reddy's: Textiles, pharma stocks bear tariffs brunt
Following US President Trump's tariff announcement, Indian pharmaceutical and textile companies experienced significant stock declines. Gokaldas Exports saw the steepest fall at 15.9%, with other text...
Nifty 50 top losers today, August 1: Sun Pharma, Dr. Reddy’s Laboratories, Adani Enterprises, Cipla and more
Indian equity markets ended Friday’s session (August 1) on a weak note, with both benchmark indices registering sharp declines. The BSE Sensex fell 585.67 points to settle at 80,599.91, while the NSE ...
Sun Pharma share: Morgan Stanley and HSBC stay positive, see upside up to Rs 1,948 on steady growth and strong India business
Sun Pharmaceutical Industries has received optimistic commentary from both Morgan Stanley and HSBC following its recent updates, with both brokerages maintaining positive ratings and expecting further...
Stocks to watch on brokerages, August 1: JSW Energy, Swiggy, TVS, Dabur, Eicher Motors, Maruti Suzuki, and Chola Finance on radar today
A flurry of brokerage activity has put several high-profile stocks in focus on Thursday, August 1. Among the names seeing active analyst commentary are JSW Energy, Dabur, Sun Pharma, Swiggy, IIFL Fina...
Nifty 50 top losers today, July 31: Adani Enterprises, Tata Steel, Sun Pharmaceutical, Dr. Reddy and more
Indian stock markets closed in the red for the second consecutive session on July 31, with the Nifty 50 slipping below the 24,800 mark. The BSE Sensex declined 296.28 points to end at 81,185.58, while...
Sun Pharma Q1 Results: Revenue rises 9.5% YoY to Rs 13,851.4 crore, net profit drops 19.6% YoY
Sun Pharmaceutical Industries Ltd. announced its financial results for the quarter ended June 30, 2025 (Q1 FY26). The company reported a steady rise in revenue but saw a notable decline in net profit ...
Nifty top gainers today, July 30: L&T, Sun Pharma, Tata Consumer Products, NTPC, Maruti Suzuki India and more
Indian stock markets wrapped up the session on a positive note on July 30, with the Nifty 50 closing at 24,855.05, marking a modest gain of 0.14%. The Sensex too edged higher by 143.91 points to finis...
Sun Pharma subsidiaries settle US antitrust litigation for $200 million
Sun Pharmaceutical Industries Limited (“Sun Pharma”) has announced that its subsidiaries, Sun Pharmaceutical Industries, Inc. (“SPII”) and Taro Pharmaceuticals U.S.A., Inc. (“Taro”), have entered into...
Sun Pharma reports positive results from Phase 3 trials for ILUMYA
Sun Pharmaceutical Industries has shared encouraging top-line results from two (Phase 3) clinical trials evaluating its biologic drug tildrakizumab 100 mg, marketed as ILUMYA®, for the treatment of ac...
Tata Technologies, Sun Pharma & more: Top stocks on brokers' radar for July 17, 2025
Brokerage firms have varying outlooks on several companies. JP Morgan downgraded Tata Technologies due to mixed Q1 results, while Goldman Sachs is optimistic about Ola Electric's path to profitability...
Nifty 50 top losers today, July 16: Shriram Finance, Eternal, Sun Pharma, Cipla, Tata Steel and more
Indian stock markets wrapped up July 16 on a quiet but positive note, with both Sensex and Nifty 50 posting modest gains. The Sensex inched up by 63.57 points to end at 82,634.48, while the Nifty 50 a...
Nifty top gainers today, July 15: Hero MotoCorp, Bajaj Auto, Sun Pharma, Shriram Finance, Apollo Hospitals and more
Indian stock markets wrapped up the day on a positive note this Monday, July 15, with both benchmark indices showing solid strength. The BSE Sensex jumped 317 points to close at 82,570.91, while the N...
Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients MUMBAI, India and PRINCETON, N.J. , July 14, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries ...
Sun Pharma announces settlement with Incyte Corporation over LEQSELVI litigation
Sun Pharmaceutical Industries Ltd announced on July 14 that it has reached a settlement and license agreement with Incyte Corporation in connection with litigation over the drug LEQSELVI™ (deuruxoliti...
Morgan Stanley turns selective on Indian pharma, initiates call on Sun Pharma, Lupin, DRL, CIPLA shares
Morgan Stanley has initiated coverage on India’s four largest pharmaceutical companies by market capitalization — Sun Pharma, Lupin, Dr. Reddy’s Labs (DRL), and Cipla — with a broadly cautious outlook...
Nomura says IPM growth accelerated to 8% in June; IPCA, Sun Pharma lead gains
Nomura has reported that India’s pharmaceutical market (IPM) grew 8% year-on-year in June 2025, driven by a recovery in acute therapies. The growth is the highest recorded in the past five months and ...
Drugs Control Administration (DCA) seizes fake Levipil 500 tablets in major Hyderabad raid
The Drugs Control Administration (DCA) in Hyderabad seized counterfeit Levipil 500 tablets, used for epilepsy treatment, from two pharmaceutical shops. The shops were falsely claiming the tablets were...
Torrent Pharma becomes India’s 5th largest drugmaker
Torrent Pharma's acquisition of JB Chemicals & Pharmaceuticals propels it to become India's fifth-largest pharmaceutical company, capturing a 4.6% market share. This deal significantly strengthens Tor...
Nifty 50 top losers today, June 17: Adani Enterprises, Dr. Reddy’s, Tata Motors, Sun Pharma lead declines
Indian equity benchmarks closed lower on Tuesday, June 17, 2025, as cautious market sentiment weighed on investor confidence. The BSE Sensex dropped 212.85 points (0.26%) to settle at 81,583.30, while...
Nifty 50 top losers today, June 16: Tata Motors, Dr. Reddy’s, Sun Pharma, Adani Ports and Jio Financial Services
Indian equity markets closed on a strong note on June 16, 2025, with broad-based gains across major sectors. The BSE Sensex surged 677.55 points (0.84%) to close at 81,796.15, while the NSE Nifty 50 g...
UBS retains ‘Buy’ on Sun Pharma stock but awaits clarity on US drug tariffs
UBS has maintained a ‘Buy’ rating on Sun Pharmaceutical Industries with a target price of ₹2,450, while flagging near-term regulatory and policy uncertainties. The brokerage noted that Sun Pharma is u...
Stocks to watch on June 17: Syngene, Tata Motors, Vedanta, YES Bank, SpiceJet, Sun Pharma, Natco Pharma, Zydus, Ramkrishna Forging
Here’s a look at the key stocks that could be in focus on June 16 based on company announcements, regulatory updates, promoter actions, and sector movements: Syngene: US FDA issues zero observations f...
Compliance review: Sun Pharma’s Halol plant gets 8 USFDA observations; company vows remedial steps after inspection
Sun Pharmaceutical Industries faces scrutiny. The USFDA issued a Form 483. This follows an inspection of its Halol manufacturing plant in Gujarat. The inspection occurred between June 2 and June 13, 2...
Sun Pharma’s Halol facility receives form 483 with 8 observations from US FDA
Sun Pharmaceutical Industries Limited, one of India’s leading pharmaceutical companies, has announced the conclusion of a recent inspection by the United States Food and Drug Administration (US FDA) a...